Murphy & Mullick Capital Management Corp Vertex Pharmaceuticals Inc Transaction History
Murphy & Mullick Capital Management Corp
- $109 Billion
- Q4 2024
A detailed history of Murphy & Mullick Capital Management Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 3,260 shares of VRTX stock, worth $1.48 Million. This represents 1.21% of its overall portfolio holdings.
Number of Shares
3,260Holding current value
$1.48 Million% of portfolio
1.21%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,717Shares Held
223MCall Options Held
1.64MPut Options Held
1.37M-
Capital World Investors Los Angeles, CA26.8MShares$12.2 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$10.6 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.38 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.1 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $117B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...